PT. RICHMOND, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 11th Annual BIO CEO & Investor Conference in New York City on Monday, February 9, 2009 at 9:30 AM Eastern Time.
An audio webcast of the presentation will be available at http://www.transcept.com. The replay of the presentation will be available for 30 days.
About Transcept Pharmaceuticals (TSPT)
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. On February 2, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) is positioned to be the first commercially available sleep aid specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.
For further information, please visit the company's website at: http://www.transcept.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Intermezzo being the first commercially available sleep aid in its target indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, or unexpected expenses incurred in connection with, obtaining regulatory approval , market acceptance and commercialization of Intermezzo(R).
Contacts: Transcept Pharmaceuticals, Inc. Michael Gill Director of Communications (510) 215-3575 email@example.com The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 firstname.lastname@example.org email@example.com
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved